An association between non-opioid analgesic agents and chronic kidney disease has long been suspected. The presumed development of chronic renal impairment following protracted and excessive use of non-opioid analgesia is known as analgesic nephropathy. Many clinicians accept analgesic nephropathy as a real entity despite the paucity of scientific evidence. This narrative review aims to summarize the literature in the field. The weight of available observational literature suggests that long-term ingestion of paracetamol and combination mixtures of aspirin and paracetamol are likely to contribute to chronic renal impairment. However, there is no convincing data to implicate non-steroidal anti-inflammatory drugs or aspirin monotherapy in the development of analgesic nephropathy. In the absence of high-level evidence, while controversy persists, it may be prudent for physicians to consider all non-narcotic analgesics to be nephrotoxic with long-term use.
INTRODUCTION
Analgesic nephropathy (AN) is a form of chronic renal insufficiency caused by long-term regular ingestion of one or more analgesic medications. Although a well-recognized condition to most physicians, its etiopathogenesis remains controversial and the particular agents known to induce AN and the cumulative doses required have not been established. Formerly one of the commoner causes of end-stage renal failure (ESRF), there has been a marked decline in the prevalence and incidence of AN in recent decades. 1, 2) At its peak in the 1980s, AN accounted for 15% to 20% of cases of ESRF, but has fallen to approximately 1% in Western countries today. [3] [4] [5] [6] [7] An association between non-opiate analgesic drugs and chronic renal impairment was first hypothesized in German literature in 1953 8) based on observations that analgesic abusers frequently developed chronic kidney disease (CKD). Phenacetin was singled out as the culprit in early reports and its widespread withdrawal from the market is a possible explanation for the dramatic decline of AN. Legislation installed globally throughout the late twentieth century restricting prescription of combination analgesics may also have contributed to this reduced incidence, and the nephrotoxicity of various non-phenacetin preparations continues to be speculated. [9] [10] [11] The true prevalence of AN is difficult to estimate because definitive diagnoses are rarely made. There are no validated objective diagnostic criteria. In the absence of other causes, it is often a diagnosis of exclusion in patients with renal impairment who report a history of analgesic abuse. Most patients are asymptomatic and middle age or older.
They frequently describe a history of chronic pain, typically headaches or low back pain. 12) Patients usually admit to having consumed regular analgesic medicines for many months or years, although they may deny or underreport their usage. Abnormal renal function is usually a serendipitous finding. Radiologic signs described in AN include atrophic kidneys, renal papillary calcification, and irregular renal contours.
This combination of features is seldom seen in other diseases. No histologic changes are diagnostic of AN, but papillary necrosis and chronic interstitial nephritis are both characteristic of the condition. 4, 5, 10) Despite a relatively large quantity of observational evidence, the relative contribution of specific drugs in the development of AN remains undetermined. Randomized controlled trials are lacking and research so far has relied upon experimental animal models or epidemiological human studies with conflicting outcomes. This narrative review intends to summarize the available literature.
PHENACETIN
Phenacetin is an analgesic antipyretic compound that is metabolized to paracetamol and other reactive intermediates. Formerly in widespread distribution, phenacetin was gradually withdrawn from markets worldwide because of adverse effects, notably its asserted propensity to induce renal impairment. Phenacetin products were the most widely sold non-prescription analgesics in the 1960s and 1970s. . 24) In a multicenter retrospective study, daily paracetamol ingestion was associated with higher risk of CKD compared with nonconsumers (OR, 3.2; 95% CI, 1.05 to 9.80). 25) Certainly the findings of these papers underscore that excessive paracetamol ingestion and CKD frequently occur together, although that does not assign the principle of causation.
Dialysis patients are more likely than control groups to have consumed long-term regular paracetamol. In an investigation by Perneger et al., 26) individuals reporting lifetime consumption of 1,000-4,999 paracetamol tablets were more likely to be current dialysis users than those who had taken 999 tablets or less (OR, 2.0; 95% CI, 1.3 to 3.2).
The likelihood of dialysis was even higher in subjects reporting lifetime ingestion exceeding 5,000 tablets (OR, 2.4; 95% CI, 1.2 to 4.8). Patients listed on the Michigan Kidney Registry, a state-wide dialysis register, are also more likely to report chronic paracetamol abuse than random civilians (OR, 2.66; 95% CI, 1.04 to 6.82). 27) As in other epidemiologic studies, these reports are vulnerable to reverse causality; ESRF patients are more likely to require paracetamol as a consequence of their general condition than are the healthy control population, and paracetamol use per se may be unrelated to the evolution of kidney impairment. Patients with known renal diagnoses were not excluded in these papers, which is important given the relative rarity of AN as a cause for ESRF.
Several publications have not demonstrated an increased risk of CKD despite paracetamol abuse. 28, 29) The National Health and Nutritional Examination Survey (NHANES), a large cross-sectional analysis of more than 8,000 random community residents, found no statistically significant difference in the chance of poor renal function between abusers of paracetamol and non-users.
2,29)

ASPIRIN
Research has failed to identify any consistent relationship between the protracted use of aspirin alone and the development of AN. No correlation was discovered in any of the aforementioned controlled studies by Curhan et al., 24) Perneger et al. 26) or Sandler et al., 25) nor was habitual aspirin use accompanied by GFR decline in the NHANES. Several small longitudinal studies of heavy aspirin users in rheumatology outpatient cohorts have also not documented any increased risk of renal impairment. 30, 31) The largest cohort trial investigating aspirin is the case control study by Rexrode et al. 32) Researchers recruited 11,032 healthy young men to complete a survey of analgesic use annually for 14 years.
Total aspirin intake was calculated for the study period and serum cre- compared with no aspirin use. The Okada study followed a complicated protocol, in which randomized arms receiving aspirin or no aspirin for 4.4 years in a separate trial were followed at that study's conclusion for a further 4.1 years. During the non-randomized phase, participants could commence or cease aspirin at their treating doctor's discretion.
At 8.5 years, 18% of the aspirin group was not consuming aspirin, while 11% of the no-aspirin group was taking daily aspirin. The null hypothesis advertised by this study is therefore less than absolute, but is nonetheless helpful as observational evidence.
A positive association between aspirin abuse and CKD has been re- 
NON-STEROIDAL ANTI-INFLAMMATORIES
The majority of large epidemiologic studies have failed to substantiate an association between heavy non-steroidal anti-inflammatory (NSAID) use and CKD in healthy individuals. The prospective paper by Curhan et al. 24) found no increased risk for renal impairment at 11 years follow-up despite regular NSAID use. Regular ibuprofen users in the NHANES had no change in renal function compared with controls. 29) There was also no link demonstrated in the case control study by Ibanez et al. 34) nor the large 14 year prospective study by Rexrode et al. 32) In a recent Italian case control study of approximately 2,000 patients with CKD and nearly 8,000 matched controls, no association was identified between high intake of NSAIDs and renal insufficiency (OR, 0.94; 95% CI, 0.84 to 1.05). 39) A multicenter European report of 4,529 dialysis patients and controls did not find abuse of any common non-phenacetin analgesics to increase the risk of ESRF (OR, 1.02; 95% CI, 0.81 to 1.28). 40) A post hoc review of subjects from the high consumption group of that study, defined as lifetime ingestion of greater than 3 kg of non-opioid non-phenacetin analgesic agents, also failed to show any correlation between NSAID monotherapy and the development of ESRF. 41) Sandler et al. 42) did observe a moderately increased risk of unexplained CKD among regular NSAID consumers versus controls in their multicenter study (OR, 2.1; 95% CI, 1.1 to 4.1). In this investigation, researchers compared the reported past analgesic usage of a cohort of 554 patients with CKD with that of a control group of 516 random community members. It is unusual that the relationship was not dosedependent, and after subgroup analysis the only cohort to maintain statistical significance was men older than 65 years of age. A large shortcoming with this paper was the lack of adjustment for patients simultaneously consuming other narcotic and non-narcotic analgesic agents. It should also be noted that the CKD group were hospitalized patients with high degrees of comorbidity and ostensibly high analgesia requirements. Additionally, 95% of NSAID users consumed various
NSAIDs rather than a select drug, making incrimination of a particular agent impossible. The few who consumed a single agent used ibuprofen or indomethacin: no matched controls were found for the ibuprofen group and the indomethacin group had no increased risk of CKD.
In the large registry study by Perneger et al., 26) the prominent finding was a potential association between paracetamol and ESRF. The NSAID group overall had no statistically significant connection to dialysis rates, but multivariate analysis revealed that the subgroup with lifetime consumption of greater than 5,000 NSAID tablets had an OR for ESRF requiring dialysis of 8.8 (95% CI, 1.1 to 71.8). The CI of this result is unreliably wide, the high-use group was small at 18 subjects, and there was no adjustment for comorbidities. Furthermore, the study populations were quite different: the intervention group contained mostly black males compared with predominantly white females in the control arm.
Chronic repeated intake of NSAIDs may hasten disease progression in patients with pre-existing kidney insufficiency. In a prospective population study of 10,184 patients with known CKD, regular NSAID use was associated with a moderately increased risk of a GFR decline greater than 15 mL/min/1.73 m 2 over 2.75 years follow-up (OR, 1.26; In women aged 30-49 years, heavy phenacetin ingestion for 11 years is significantly more likely to be associated with elevated serum creatinine levels compared with minimal use (6.7% vs. 0.9%, P=0.001). Curhan et al. 24) (2004) Lifetime consumption of 100-499 g of paracetamol is associated with a decline of GFR of at least 30 mL/min/1.73 m 2 over 11 years, compared with cumulative paracetamol intake of less than 100 g (OR, 1.80; 95% CI, 1.02 to 3.17). Lifetime consumption of 500-2,999 g of paracetamol is associated with a decline of GFR of at least 30 mL/min/1.73 m 2 over 11 years, compared with cumulative paracetamol intake of less than 100 g (OR, 2.33; 95% CI, 1.36 to 3.63). Rexrode et al. 32) (2001) There is no difference in the risk of reduced creatinine clearance (≤55 mL/min) following cumulative ingestion of greater than 2,500 aspirin tablets over the preceding 14 years compared with cumulative intake of less than 12 tablets over that time (relative risk, 1.2; 95% CI, 0.8 to 1.8). Fored et al. 38 ) (2001) The likelihood of intrinsic CKD with regular combination therapy of aspirin and paracetamol is significantly greater than with regular monotherapy with aspirin (OR, 2.2; 95% CI, 1.4 to 3.5). Ingrasciotta et al. 39) (2015) There is no relationship between the prescription of non-steroidal anti-inflammatory for greater than 1 year and the risk of development of CKD (OR, 0.94; 95% CI, 0.84 to 1.05).
GFR, glomerular filtration rate; OR, odds ratio; CI, confidence interval; CKD, chronic kidney disease.
https://doi.org/10.4082/kjfm.2016.37.6.310 95% CI, 1.04 to 1.53). 43) Several smaller cohort and case control studies have supported these findings.
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DISCUSSION
The development of renal insufficiency as a consequence of chronic analgesic consumption remains unproven despite a large body of epidemiologic research. The hypothesis of AN is untested in randomized trials and supportive data is largely circumstantial (Table 1) . Non-narcotic drugs comprise a broad class and the role of specific agents in the genesis of AN is unknown. Furthermore, the precise duration and cumulative dosage necessary to induce nephrotoxicity has not been de- in Germany. 48) They concluded that the theory of nephropathy caused by any non-phenacetin non-opioid analgesic cannot be confidently supported or refuted. Phenacetin admixtures were the only agents believed capable of generating nephropathy beyond reasonable doubt.
However, several important papers have been published since these meetings, which should also be taken into consideration. 24, 29, 32, 34) Most nephrologists accept AN as a real entity despite an absence of firm evidence. 3) There is a pressing need for randomized trials to assess the true incidence of renal impairment related to specific agents, although the ethics and practicalities may make such a proposal unfeasible. While much of the accumulated supporting data is inconclusive, clinical practice should be founded on the best available evi- There is insufficient evidence to answer the hypothesis that any non-narcotic non-phenacetin analgesics can produce CKD with heavy consumption.
CKD, chronic kidney disease.
dence. Most authorities suggest that prevention is a rational approach to management, and until outstanding issues are settled it may be a matter of good clinical judgment to consider all non-opioid analgesics nephrotoxic and to avoid prolonged use where possible. 
CONCLUSION
